Moderna and Merck Report Positive Results from mRNA Cancer Vaccine Trial
Moderna (MRNA) and Merck (MRK) announced promising clinical data for their experimental cancer vaccine, intismeran autogene, combined with Keytruda. The treatment showed a 49% reduction in the risk of recurrence or death and a 50% decrease in distant metastasis compared to Keytruda alone.
Topics: biotech cancer vaccine immunotherapy pharmaceuticals